Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Kidney Dis. 2011 Feb;57(2):291-9. doi: 10.1053/j.ajkd.2010.09.021. Epub 2011 Jan 6.

Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis.

Author information

1
Department of Pediatrics, The University of Texas Medical School at Houston, USA.

Abstract

BACKGROUND:

Membranoproliferative glomerulonephritis types I (MPGN-I) and II (MPGN-II) are rare diseases that in limited case series have been reported to recur frequently in kidney transplants and have a negative impact on allograft survival.

STUDY DESIGN:

Retrospective database review.

SETTING & PARTICIPANTS:

189,211 primary kidney transplants in the United Network for Organ Sharing (UNOS) database from September 1987 to May 2007.

PREDICTOR OR FACTOR:

MPGN-I (811 patients; 0.4%), MPGN-II (179 patients; 0.1%), other GN (58,129 patients; 30.7%), and all other diagnoses (130,092 patients; 68.7%).

OUTCOMES:

Death-censored and non-death-censored allograft survival.

RESULTS:

Compared with controls, patients with MPGN-I and MPGN-II were significantly younger at the time of transplant, with a median age of 36 and 27 years compared with 44 years in the GN group and 46 years in all other disease groups, respectively (all P < 0.001). Mortality in patients with MPGN-I (8.8%) was significantly lower compared with the GN (11.3%; P = 0.02) and other disease (16.6%; P < 0.001) populations and lower in those with MPGN-II (9.5%) compared with the other disease (16.6%; P = 0.01) population. Graft failure rates were significantly higher in the MPGN-I (44.5%) cohort, but not in the MPGN-II (45.3%) cohort compared with the GN (38.0%) population (P < 0.001 and P = 0.05, respectively); neither MPGN cohort differed from the other disease (43.0%) population (P = 0.4 and P = 0.5). Overall, 10-year death-censored graft survival was similar for MPGN-I (56.2%) and MPGN-II (57.5%); both were significantly worse than for GN (65.2%; P < 0.001 and P = 0.003, respectively), and only MPGN-I was significantly worse than the other disease (60.0%) population (P = 0.004). Of allograft failures with a reported cause, disease recurrence was the primary cause in 36 (14.5%) MPGN-I and 18 (29.5%) MPGN-II transplant recipients and was significantly higher compared with 879 (6.6%) GN and 1,319 (4.4%) all-other-disease recurrence failures (P < 0.001).

LIMITATIONS:

Limited pretransplant clinical and biopsy data.

CONCLUSIONS:

A diagnosis of MPGN-I or MPGN-II has a significant negative impact on overall primary allograft survival compared with other forms of glomerulonephritis, whereas only MPGN-I has a significant, but modest, negative effect compared with other causes of end-stage renal disease.

PMID:
21215503
DOI:
10.1053/j.ajkd.2010.09.021
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center